Management of severe aortic stenosis: the Singapore and Asian perspective

Edgar Lik Wui Tay\(^1,2\), MBBS, FACC, Jinghao Nicholas Ngiam\(^1\), MBBS, William KF Kong\(^1,2\), MBChB, FRACP, Kian-Keong Poh\(^1,2\), FRCP, FACC

Management of aortic valve stenosis (AS) has seen a significant resurgence of interest in the past decade, as shown in the increasing number of publications on the topic and international valve conferences pertaining to valve-related diseases. This growth has been largely driven by the evolution of treatments available for this condition. While the options were previously largely surgical, the emergence of transcatheter aortic valve replacement (TAVR) has changed the landscape.\(^3\) In addition, closer collaboration among heart teams and imaging advances in echocardiography and computed tomography have contributed to the rapid change. The recently updated American College of Cardiology guidelines on the management of valvular heart disease reflected this.\(^2\) The pace of change in Asia, however, appears less dramatic compared to that in the United States and Europe. This article described the unique characteristics of the Asian cohort and their impact on the contemporary management of aortic stenosis.

EPIDEMIOLOGY IN ASIA

Asia is the largest continent in the world and consists of markedly heterogeneous ethnicities. The geographic differences in life expectancy rates (marked range of 62.2–83.7 years at birth) provide further insights on the varying aetologic burden of AS across Asia, according to statistics from the World Health Organization.\(^9\) Given that the probability of degenerative AS only increases significantly after 75 years of age, some Asian patients do not have time to develop degenerative AS. In addition, childhood rheumatic fever rates also vary significantly among Asian countries. Currently, rheumatic aortic stenosis is most common in Asia, with a reported prevalence of 1.86 in China, 4.54 in India, and 1.3 in Bangladesh per 1,000 population. However, it is important to note that several Asian countries, including Singapore, mirror Western cohorts in having a very low prevalence of rheumatic valvular disease (e.g. 0.14 in Japan and 0.5 in South Korea per 1,000 population). This has significant implications, as rheumatic AS patients often present at a younger age and most would benefit from conventional open heart surgery.\(^1\) On the other hand, Singapore (similar to Japan and South Korea) has a high proportion of elderly with degenerative AS, and correspondingly, the uptake of TAVR is increasing.

ANATOMIC DIFFERENCES

Compared to Caucasian patients, most Asians with AS have a smaller body surface area, which affects the choice of therapy. Using computed tomography, we have demonstrated that the aortic annuli of Singaporean patients are smaller (unpublished study). Other studies have suggested that their iliofemoral arterial sizes are also smaller.\(^1\) While this may affect the TAVR approach, the availability of small French sizes (e.g. in the Evolut R systems) delivery systems allow for a transfemoral route when the femoral sizes are 5 mm and above. Nevertheless, in patients who have borderline femoral sizes with calcification and peripheral vascular disease, this remains important. Overall, the number of patients requiring the transapical approach has reduced significantly over the years, as observed in the Society of Thoracic Surgeons/ American College of Cardiology Transcatheter Valve Therapy Registry.\(^4\)

The Japanese TAVR cohorts have a smaller aortic root annular diameter (20.4 ± 1.46 mm vs. 22.0 ± 1.84 mm; p < 0.01).\(^2\) This may result in more difficult transfemoral access patients for TAVR and may lead to the increased utilisation of alternative access sites. In contrast, for patients with very small annuli, surgeons may be reluctant to perform a root enlargement procedure and may prefer TAVR in some cases. Recent studies on bicuspid valves have also shed light on important interethnic differences. Asians tend to have Type I bicuspid valves with larger aortic root dimensions compared to Western cohorts. This information would have a significant impact on device sizing when the TAVR technology is expanded to younger patients, in whom a higher proportion of aortic stenosis cases have a bicuspid aetiology.\(^5\)

Left ventricular outflow track (LVOT) annular size affects classification of AS as well.\(^6\) Michelena et al investigated whether LVOT diameters are a source of inconsistencies in the echocardiographic severity grading of AS based on transaortic gradients and aortic valve areas (AVAs). They divided patients into small, average and large LVOT diameters of 1.7–1.9 cm, 2.0–2.2 cm and ≥ 2.3 cm. The study found that an AVA cutoff of 0.8 cm\(^2\) and 0.9 cm\(^2\), respectively, reduced severe AS categorisation inconsistency for patients with small LVOT diameter and average LVOT diameter. The current guideline’s AVA cutoff of 1 cm\(^2\) was consistent for patients with large LVOT diameter.\(^6\) In our institution’s retrospective database of 1,690 echocardiograms with isolated AS, 40%, 48% and 12% had LVOT diameters of 1.7–1.9 cm, 2.0–2.2 cm and ≥ 2.3 cm, respectively. This differs from Michelena et al’s series of 9%, 56% and 35%, respectively.\(^6\) For severe AS, our proportions were 52%, 31% and 17%, respectively (from an unpublished study). This large proportion of local subjects with small LVOT diameters may imply that we should have a lower cutoff for

---

1Department of Cardiology, National University Heart Centre Singapore, National University Health System, *NUS Yong Loo Lin School of Medicine, National University of Singapore, Singapore
2Department of Medicine, National University Health System, Singapore

Correspondence: A/Prof Kian-Keong Poh, Department of Cardiology, National University Heart Centre Singapore, National University Health System, 1E Kent Ridge Rd, NUHS Tower Block, Level9, Singapore 119228. kian_keong_poh@nuhs.edu.sg
classifying patients into the severe AS category. Another recent study also demonstrated a large number of bicuspid aortic valves among AS patients in China who were screened for TAVR with computed tomography, a significantly higher number than in other Asian studies published thus far. \(^{(10)}\) We postulate that the differences from Western cohorts may be related to the age of patients in the Chinese cohort compared to the other registries. This trend warrants further investigation, as it has implications for the treatment of AS patients with bicuspid valves. Currently, TAVR in this group remains off-label, as patients with severe bicuspid AS are associated with increased procedural complexity, and possibly inferior outcomes in the form of lower procedural success and an increase in peri-procedural complications, although a published study did not demonstrate a significant difference in long-term mortality. \(^{(11)}\) Several Chinese hospitals have independently treated many of these patients with success. \(^{(12)}\)

The specific subgroup of paradoxical low-flow AS despite preserved left ventricular ejection fraction (LVEF) remained an important group that was challenging to manage. The proportions of low-flow severe AS (stroke volume index < 35 mL/m\(^2\)) with preserved LVEF in our series were similar to those of Western populations. This group of subjects appeared to have similar clinical outcomes compared to normal-flow AS in a paired echocardiographic analysis. \(^{(13)}\) We have also described that the paradoxical low-flow phenomenon was present even in moderate aortic stenosis. \(^{(14)}\) The outcomes of valve replacement (whether transcatheter or surgical) in this subgroup of patients in our Asian context have yet to be further elucidated.

**SURGICAL RISK SCORE AND FRAILTY**

Assessment and selection of AS patients for open surgery or TAVR is performed by a heart team consisting of cardiac surgeons and interventionists. In our institution, these cases were discussed in a valve forum led by non-invasive cardiologists with interest in valvular heart disease. In most instances, an integrative approach is used, which assesses comorbidities and utilises surgical risk scores (STS), clinical history and physical assessment, including assessment of frailty, before a decision on the best-suited therapy is made. While these risk scores were not validated for the Asian cohort, several studies have utilised the STS with good predictability. A recent objective clinical frailty scale used in a Japanese cohort showed good discriminability to exclude frail patients for whom invasive therapy would be futile. \(^{(15)}\)

**THERAPY OPTIONS**

Open aortic valve surgery remains the most common treatment option for AS in Asia. Its key advantages are the long history and experience of cardiac surgeons in this region. Most of the studies available in the existing literature are retrospective and include patients with an age range of 70–80 years. The reported short-term outcomes are good and show no significant differences among types of prostheses.

The decision-making process regarding the choice of prosthesis (metallic vs. bioprosthetic) recommended by Asian surgeons differs slightly from that of their Western counterparts. Utilising only the recommended age-related cutoff may not be applicable in many Asian sites. This is because life expectancy in different parts of Asia differs not only based on cardiac condition, systemic illnesses and gender, but also socioeconomic status and specific geographic location. The types of valves selected are also determined by cost, availability of the site to monitor the patient and ease of access to anticoagulation treatment and monitoring (apart from the patient’s preference and life expectancy).

**THE FUTURE OF TAVR**

TAVR has been available in Asia for the past eight years, enabling many more patients to undertake treatment. Starting from Singapore, it is now available in many Asian cities, with Japan having the largest number of implants to date. Of note, a Singaporean study showed that a large proportion of patients declined open surgery despite being told of its benefits. \(^{(16)}\) This mirrors the mindset of patients in Asia, who often fear open surgery.

Despite this, the adoption of TAVR in Asia compared to the United States and Europe has been comparatively slow. The high cost of treatment remains a significant barrier to its uptake, largely due to the lack of full reimbursement for TAVR in most parts of Asia (the only exception being Japan). The high upfront cost of the implant remains prohibitive to many patients compared to traditional open heart surgery, which has much lower implant costs. Cost-effectiveness data from Singapore is unavailable. To remedy this, two projects are currently ongoing in our unit. The first, a value-driven outcomes analysis to determine the true cost of the TAVR procedure and the true value to the patient, would enable us to study opportunities to lower the cost of the procedure while maintaining optimal outcomes for patients. The second is a traditional cost-effectiveness analysis to determine if the cost of TAVR fulfils the institution’s approved incremental cost-effectiveness ratio ranges, so that longer-term reimbursement becomes possible. Further challenges in the uptake of TAVR in Singapore and Asia include possible under-diagnosis of AS in the Asian population. Lack of awareness also remains a challenge, as many patients, even those diagnosed with severe AS, still do not know that TAVR is available as a treatment option.

Despite these challenges, the outcomes of TAVR for AS patients remain promising. \(^{(17,18)}\) Regionally, several innovative projects in transcatheter heart valve development are being undertaken, and may improve the availability of Asian-made valves. For example, the Venus A-valve from China is now commercially available in mainland China, with the MicroPort valve being evaluated as well. In India, the Myvalve is being utilised in a clinical trial, while Thailand has developed the Hydra valve in parallel. \(^{(19)}\) These innovations may further fuel the growth of TAVR.

Singapore is fortunate to have early access to therapies via several special access routes, as well as the availability of most commercialised transcatheter valves. In addition, both the Asian TAVR registry \(^{(20)}\) and the Japanese OCEAN-TAVI (Optimized Transcatheter Valvular Intervention) registry \(^{(21)}\) have published clinical outcomes demonstrating success in patient selection and the safety of the therapy. As with the Western cohorts, there
is a gradual shift in which TAVR is increasingly being offered to patients of intermediate and even lower surgical risk, although cost remains an important consideration. It is anticipated that the utilisation of TAVR in Asia will continue to expand as more patients learn about this treatment.

REFERENCES